AHA comments to DEA on 2019 controlled substances quotas
The AHA Aug. 28 urged the Drug Enforcement Administration to reconsider its proposed 2019 aggregate production quotas for certain controlled substances, which the agency said would reduce manufacturing quotas for six frequently misused opioids by an average 10 percent. 鈥淗ospitals and other providers are currently facing critical shortages of a number of injectable opioid medications for which that the DEA recommends quota reductions, including morphine, hydromorphone, and fentanyl,鈥 AHA said in a letter to DEA. 鈥淭hese decreases would exacerbate these already dire shortages.鈥 AHA said its request is 鈥渟pecific to these injectable medopications and does not extend to other dosage forms or opioid products.鈥 Comments are due Sept. 19.
Related News Articles
Headline
The Government Accountability Office yesterday released a report calling for the Department of Health and Human Services to improve its efforts responding to鈥
Headline
The Food and Drug Administration Jan. 30 announced it approved Journavx (suzetrigine) oral tablets, a first-in-class non-opioid drug, to treat moderate to鈥
Headline
In this conversation, Vinnidhy Dave, D.O., hospice specialist and director of palliative medicine at Englewood Health Physician Network, and Lauren Savage,鈥
Headline
In this conversation, Matthew Hoag, director of integrated behavioral health at Denver Health, shares how the organization is innovating through integration to鈥
Headline
The AHA June 7 submitted comments on a discussion draft of the Drug Shortage Prevention and Mitigation Act, bipartisan legislation proposing to provide鈥
Blog
The inability of many patients to obtain needed drug therapies due to either high prices or shortages has negatively affected patient outcomes.1 Nearly 30% of鈥